Yahoo · Sep 18, 2026
Biotech Options Buzz: UTHR, NMRA, EWTX
UTHR, NMRA, and EWTX are drawing attention from options bears
NM
NASDAQ · NMRA
Neumora Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
$0.47
Down-$0.01 (-1.35%)
Updated Oct 8, 2026, 5:36 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 346.56M
- P/E ratio
- -1.42
- Dividend yield
- 0.00%
- 52-week range
- $0.47 – $3.52
- Volume
- 2.76M
- Avg. volume
- 1.61M
Price performance · NMRA
NMRA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
NMRA closed at $0.47 after 21 trading sessions, down 60.98% for the selected period.
- Last close
- $0.47
- Period change
- -60.98%
- Period low
- $0.47
- Period high
- $1.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $0.4647 | $0.4819 | $0.4514 | $0.4683 | 2.76M |
| Oct 6, 2026 | $0.5253 | $0.539 | $0.47 | $0.471 | 1.23M |
| Oct 5, 2026 | $0.50 | $0.5336 | $0.4717 | $0.5253 | 2.99M |
| Oct 2, 2026 | $0.5595 | $0.5595 | $0.4801 | $0.4999 | 2.69M |
| Oct 1, 2026 | $0.6001 | $0.62 | $0.54 | $0.55 | 2.85M |
| Sep 30, 2026 | $0.6776 | $0.6891 | $0.5902 | $0.5962 | 2.29M |
| Sep 29, 2026 | $0.688 | $0.7164 | $0.65 | $0.6776 | 1.25M |
| Sep 28, 2026 | $0.648 | $0.7469 | $0.641 | $0.6918 | 3.41M |
| Sep 25, 2026 | $0.692 | $0.711 | $0.6327 | $0.6776 | 2.32M |
| Sep 24, 2026 | $0.7461 | $0.7728 | $0.693 | $0.7031 | 1.43M |
| Sep 23, 2026 | $0.7677 | $0.7785 | $0.6903 | $0.7313 | 1.69M |
| Sep 22, 2026 | $0.6961 | $0.8111 | $0.69 | $0.7785 | 3.21M |
| Sep 21, 2026 | $0.7371 | $0.77 | $0.6805 | $0.6918 | 1.68M |
| Sep 18, 2026 | $0.741 | $0.7642 | $0.71 | $0.73 | 3.88M |
| Sep 17, 2026 | $0.78 | $0.8082 | $0.7316 | $0.75 | 3.42M |
| Sep 16, 2026 | $0.8442 | $0.8921 | $0.76 | $0.7732 | 3.22M |
| Sep 15, 2026 | $1.02 | $1.03 | $0.83 | $0.8313 | 1.42M |
| Sep 14, 2026 | $1.03 | $1.06 | $0.99 | $0.9994 | 555.26K |
| Sep 11, 2026 | $1.16 | $1.16 | $1.02 | $1.04 | 1.88M |
| Sep 10, 2026 | $1.20 | $1.21 | $1.115 | $1.14 | 600.85K |
| Sep 9, 2026 | $1.26 | $1.265 | $1.19 | $1.20 | 586.95K |
Latest NMRA news
The latest Smart Investors Daily articles mentioning NMRA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NMRA research
Overview
Company profile and research snapshot.
Company profile
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | RBC Capital | Outperform | — |
| Jun 18, 2026 | Mizuho | Outperform | — |
| Jun 16, 2026 | Needham | Buy | — |
| Jun 16, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
Benzinga · Aug 14, 2026
Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share
Benzinga · Jul 31, 2026
Why Is BioAge Labs Stock Sinking Friday?
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
